Markets firm/Pharma mixed; Close +$0.01, $0.77, 167k; 65k Germany; 0 shares US | SVA:CA Message Board Posts


SVA:CA   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  2517 of 2611  at  11/23/2022 5:45:37 PM  by

jwallisca


Markets firm/Pharma mixed; Close +$0.01, $0.77, 167k; 65k Germany; 0 shares US

Mr. House Positions:
 
Re your comment: "Looks like a nice BB (20,2.0) bounce off the lower band. We'll see tomorrow?", we can but hope it'll happen!
 
Lots of good posts here: https://ceo.ca/sva
 
Sampling:
 
 
Comment: @JWCEO Sernova never announces a new presentation even now with share price under pressure! A news release with a little explanation of all the goodies rather than having to hunt for it would be much better. No promotion ever is the mantra! Time for a Big Change! 🤔😵‍💫🦨🦨🥱💤🙈🙉🙊🤺
 
2) @JWCEO https://medcitynews.com/2022/11/mercks-1-3b-imago-buyout-brings-blood-cancer-drug-to-rival-bms-incyte-gsk/? That's about C$5.5/SVA share. The drug is in FDA trial with positive results, but Not a Functional Cure! SVA'S so undervalued thanks to Sernova's intransigence! 🤔🐁🐁👀⏰️☎️❓️🙈🙉🙊🦨🥱💤
 
3) @JWCEO This is for Hemophilia B. Each, onetime treatment is to be priced at U$3.5 million. Where's Sernova with Hemophilia A? New therapies are happening all of the time, but Sernova's asleep at the "Go" switch. Excerpt: The FDA has approved the first hemophilia B gene therapy, a one-time treatment that addresses a root cause of this inherited disorder and potentially eliminates the need for regular infusions that patients currently receive to prevent bleeding episodes. Removing that economic burden from patients and the healthcare system the comes with a premium upfront price: $3.5 million for a single infusion. The regulatory approval announced late Tuesday for the CSL Behring therapy covers adults who receive prophylactic infusions or have a history of life-threatening bleeding, as well as those who have repeated and serious spontaneous bleeding episodes. The gene therapy, known in its development as etranacogene dezaparvovec, will be marketed under the name “Hemgenix.” https://medcitynews.com/2022/11/csls-gene-therapy-approval-marks-first-for-hemophilia-b-and-new-high-in-pricing/?
 
 
We wait to see whether the Bollinger Band Bounce will happen. Thanks Mr. House positions for the heads-up!
 
Based on the presentation link above, it's clear that changes must happen in Sernova. This is no longer optional. Sernova has so much, but is being run like a loss leader in a grocery store: attract initial attention and then viewer moves on to other shopping [of companies]. No Volume, No Interest, No New Money!
 
SVA continues to be played. A 104.5k Ask sandbag at C$0.80 arrived late in the trading day to prevent a move above 80 cents. It's now gone: we've seen this before. Note that Integral Wealth [House 17] is the biggest net buyer of Sernova shares so far this week, unbelievable! I repeat: No Volume, No Interest, No New Money!
 
jwall
 
 
 
 

---------------------------------------

Sent: 11/23/2022 4:37:02 PM
Subject: Looks like a nice BB (20,2.0) bounce off the lower band. We'll see tomorrow?
 
Today:
 
 
Week so far:
 
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 2  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...